Oligodendroglioma clinical trials at UCSF

2 in progress, 1 open to eligible people

Oligodendroglioma is a type of brain tumor. UCSF is running a study to test the effects of combining Vorasidenib and Pembrolizumab in people with recurring or worsening IDH-1 mutant glioma. This trial aims to explore new treatment options for these brain tumors.

Showing trials for

  • Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

    open to eligible people ages 18 years and up

    Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.

    San Francisco, California and other locations

  • Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

    Sorry, in progress, not accepting new patients

    This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.

    San Francisco, California and other locations

Last updated: